The Honest Supplement Guide for Men Over 40

Opening Scene

Two patients. Different weeks. Same fundamental problem.

The first was forty-four, a commercial real estate developer, who sat down and placed a printed spreadsheet on my desk before I had finished reading his chart. He had been maintaining this list for three years. Twenty-seven supplements. He wanted to know which ones were doing something.

“I spend about two hundred and twenty dollars a month,” he said. “And I genuinely cannot tell you whether any of them are working.”

The second was thirty-eight, an IT project manager, who had been taking creatine monohydrate consistently for two years. He had noticed, he said, real improvements in the gym. Real improvements in cognition during mentally demanding stretches. Then a colleague had told him: creatine causes hair loss. He had read about it online. He had stopped taking it three weeks ago. He was now also not sleeping well, which he was attributing to creatine withdrawal (there is no such thing), and he wanted to know if the hair loss risk was real.

These two men represent the two primary supplement failure modes in men over 40. The first is supplement sprawl: a growing stack assembled from podcasts, fitness influencer recommendations, and longevity protocol content, with no evidence hierarchy, no prioritization, and no physician input. The second is supplement fear: a single, well-supported supplement abandoned based on a single, never-replicated study, because the correct information was not available in the right format at the right moment.

Both failures stem from the same root cause: the supplement conversation in men’s health does not have a reliable, clinically grounded, commercially independent voice. What it has instead is Peter Attia’s complexity, Huberman’s protocol density, David Sinclair’s longevity optimism, Bryan Johnson’s 111-compound list, Gary Brecka’s genetic testing upsells, and Paul Saladino’s organ supplement promotion. All of these voices have genuine expertise in some domains. None of them are practicing cardiologists with an obligation to prioritize cardiovascular endpoints above all else.

That is what this piece is. A clinical hierarchy of the supplement evidence for men over 40, organized around what I actually see matter in outcomes, applied with the Honesty Scale in real time.

I am going to address three sub-domains: creatine, protein, and micronutrients. Each gets its own Honesty Scale. I will tell you what works, what probably works, what we do not yet know, and what is being sold to you on the basis of mechanism and optimism rather than clinical evidence.

Let’s go.

What Most Men Hide About Supplements

Men in their forties have a complicated relationship with supplements that is harder to characterize than simple credulity.

Many of the men I see are intelligent, evidence-conscious, and professionally accomplished. They know, on some level, that not everything in their stack is evidence-based. What they are doing is not gullibility. It is something more like managed hope: the stack represents active agency over a aging process that feels increasingly out of control. Stopping it feels like surrender.

What they say online captures this tension:

“I’ve been taking creatine for two years and someone just told me it causes hair loss. Now I’m freaking out and I’ve stopped. But I want to know if the study is real.” (r/Fitness)

“I’ve been following Huberman’s supplement protocol for eight months. The ashwagandha, the magnesium threonate, the tongkat ali. I honestly feel better. But I have no idea if that’s the supplements or the fact that I’ve also been sleeping better and exercising more.” (r/HubermanLab)

“I spend $200 a month on supplements. I’m not sure I can even tell you what half of them do. I started them because I was feeling run-down at 43 and I didn’t know what else to do.” (r/over40fitness)

What is hidden in these statements is not ignorance. It is the absence of a trustworthy clinical frame. These men are not asking to be told supplements are useless. They are asking someone to tell them the truth about which ones are worth the money and which ones are not. That is a reasonable ask, and the consumer health content space has failed to answer it cleanly.

Here is my attempt.

PART ONE: CREATINE

The Mechanism, In Plain English

Creatine is the most extensively studied dietary supplement in existence. This is not a marketing claim. It is a bibliometric fact: over 500 peer-reviewed trials have examined creatine safety and efficacy across multiple populations, spanning thirty years of research.

The mechanism is well-established and relatively simple. Creatine is stored in muscle as phosphocreatine. During high-intensity, short-duration exercise, phosphocreatine donates a phosphate group to ADP, rapidly regenerating ATP, the energy currency of muscle contraction. This process is rate-limiting for explosive efforts lasting 1 to 10 seconds, meaning creatine supplementation directly improves performance in resistance training, sprinting, and similar activities by extending the capacity for maximal effort.

At 3 to 5 grams per day, creatine monohydrate consistently produces: increased maximal muscle strength (effect size approximately 5 to 15%), increased lean muscle mass over 4 to 12 weeks of training, and in older adults specifically, attenuation of age-related muscle loss (sarcopenia). There is also accumulating evidence, from studies with adequate statistical power, for cognitive benefit in tasks requiring working memory, particularly under sleep deprivation, an effect plausibly mediated by creatine’s role in cerebral energy metabolism.

Creatine monohydrate at 3–5 g/day is the most extensively studied dietary supplement in existence, with over 500 peer-reviewed trials confirming safety and efficacy across multiple populations. Its mechanism is established: phosphocreatine donation to ADP during maximal-effort activity rapidly regenerates ATP and extends the capacity for explosive muscular contraction. At standard doses, there is no demonstrated effect on DHT levels, kidney function in healthy men, or hair loss. The one study that generated the hair loss claim used a loading dose of 25 g/day and has never been replicated.

The Hair Loss Question: What the Study Actually Said

In 2009, van der Merwe and colleagues published a small study in the Clinical Journal of Sport Medicine. Twenty male rugby players were randomized to creatine loading (25 g/day for 7 days, then 5 g/day for 14 days) or placebo. The creatine group showed a statistically significant increase in serum DHT (dihydrotestosterone) levels relative to placebo, with DHT rising approximately 56% in the loading phase (van der Merwe et al., Clinical Journal of Sport Medicine, 2009).

DHT, for those who are not familiar, is the androgen most strongly associated with androgenic alopecia (male-pattern baldness) in men with the relevant genetic predisposition.

Here is what the study did not show: any participant developed hair loss. No hair loss was measured. No DHT receptor sensitivity analysis was performed. Total testosterone was unchanged. The DHT elevation remained within the normal reference range.

Here is what twenty-three years of creatine research that preceded and followed this study has consistently not shown: standard-dose creatine (3 to 5 g/day) raising DHT above the normal range in any replicated study. The van der Merwe study has not been replicated. Its loading dose of 25 grams per day is three to five times the dose men typically take and clinicians typically recommend.

The man in my opening scene who stopped taking creatine based on this study made a medical decision based on a single non-replicated study using an atypical dose, which measured a surrogate marker (DHT) that did not produce the feared outcome (hair loss) in any participant. He did this because the correct clinical interpretation of that study was not available to him in a format he could use.

The single study linking creatine to elevated DHT used a loading dose of 25 g/day and has never been replicated; standard dosing of 3–5 g/day has no proven effect on DHT above the normal range, hair loss, or kidney function in healthy men. Creatine monohydrate at standard doses is among the safest supplements available, with the strongest evidence base in the entire dietary supplement literature ([Rawson and Venezia, Current Sports Medicine Reports, 2011](https://doi.org/10.1249/JSR.0b013e318228b #8e6)).

Creatine Honesty Scale

• Creatine monohydrate for muscle strength and lean mass in resistance-training men: Solid (1), Extensive replication across populations, dose ranges, and training protocols.

• Creatine for sarcopenia attenuation in men over 50: Solid (1), Consistent evidence for additive benefit to resistance training in older men; effect independent of athletic status.

• Creatine for cognitive performance (working memory, mental fatigue): Promising (2), Emerging but consistent evidence in cognitively demanding tasks and under sleep deprivation; effect size moderate; does not apply to well-rested men with adequate dietary creatine.

• Creatine causing hair loss at standard dosing: Unsupported (5), Zero replicated evidence. One non-replicated study using five times the standard dose measured a DHT marker that did not produce hair loss in any participant.

• Creatine causing kidney damage in healthy men at standard doses: Unsupported (5), Multiple studies specifically examining kidney function in healthy men taking creatine long-term show no clinically significant changes in serum creatinine interpretation is confounded by creatine’s metabolism, but eGFR and cystatin C are normal.

PART TWO: PROTEIN

The Mechanism, In Plain English

The second supplement conversation that men over 40 need to have is not, technically, about supplements. It is about a macronutrient that most men consume through food but rarely at the doses the evidence supports.

After age 40, and accelerating after 50, muscle protein synthesis becomes less efficient per gram of protein consumed. This is anabolic resistance: the blunted muscle-building response to dietary protein that explains why a fifty-year-old man who eats the same protein as a twenty-five-year-old builds less muscle and loses more. It also explains why the RDA for protein (0.8 g/kg/day) is deeply insufficient for men in this age group who wish to maintain muscle mass, metabolic rate, and functional strength.

The evidence-based target is 1.6 to 2.2 grams of protein per kilogram of body weight per day. For an 85-kilogram (187-pound) man, that is approximately 136 to 187 grams per day. Most men eating a typical Western diet consume 70 to 100 grams. The gap is significant.

Men over 40 require 1.6–2.2 g of protein per kilogram of body weight per day, roughly double the RDA, to counteract anabolic resistance (the age-related decline in muscle protein synthesis efficiency per gram of protein consumed). This protein should be distributed across 3–4 meals of at least 25–40g each to exceed the leucine threshold of approximately 2–3g leucine per meal, which is required to maximally activate mTOR-mediated muscle protein synthesis. Distributing the same total protein intake across smaller meals blunts the anabolic signal regardless of the total daily amount (Churchward-Venne et al., Nutrition and Metabolism, 2012).

The leucine threshold deserves specific attention. Leucine is the branched-chain amino acid that most potently activates mTOR, the cellular signaling hub that initiates muscle protein synthesis. There appears to be a threshold of approximately 2 to 3 grams of leucine per meal below which mTOR activation is incomplete, and a point of diminishing returns above which additional leucine does not further increase synthesis. This means that a 150-gram daily protein target spread across six small meals of 25 grams each produces less anabolic stimulus than three larger meals of 50 grams each, because only the 50-gram servings reliably clear the leucine threshold.

Protein powder functions as a convenient, cost-effective method to meet these targets, not as a special supplement with unique properties. Whey protein’s particular advantage is its leucine content: approximately 10 to 11% of its amino acid composition is leucine, higher than most plant proteins. This makes it effective at clearing the leucine threshold in smaller servings. Pea protein concentrate, adequately dosed, performs comparably to whey in recent head-to-head trials.

The question I am most often asked on this topic is whether Gabrielle Lyon’s claims about protein are supported by evidence. The short answer: largely yes, on the mechanistic and clinical evidence. Her emphasis on the leucine threshold, the anabolic resistance of aging muscle, and the inadequacy of the RDA for older adults is consistent with the peer-reviewed literature. The specific framing that protein is the primary lever of metabolic health (above carbohydrate management or fat quality) is a hierarchy that reasonable nutrition scientists disagree on, but it is not unsupported. Her work is among the more evidence-grounded in the consumer protein space, with the caveat that her promotional content is tied to supplement partnerships that should be noted (Lyon, Forever Strong, YouTube).

Protein Honesty Scale

• 1.6–2.2 g/kg/day protein target for muscle preservation in men over 40: Solid (1), This range is supported by multiple systematic reviews and is the target of the International Society of Sports Nutrition position stand.

• Leucine threshold (2–3g leucine per meal) for mTOR activation: Solid (1), Well-replicated in multiple mechanistic and clinical studies across age groups.

• Whey protein powder as a convenient method to meet daily targets: Solid (1), When used to supplement dietary protein to evidence-based targets, effect is equivalent to food-based protein sources.

• High protein intake (2.2 g/kg) causing kidney damage in healthy men: Unsupported (5), Multiple long-term studies in healthy men, including athletes consuming 3+ g/kg, show no decline in kidney function.

• Protein as the primary driver of metabolic health over carbohydrate quality and fat quality: Promising (2), Evidence supports high protein as metabolically favorable; “primary driver” framing is contested and depends on the metabolic outcome being measured.

PART THREE: MICRONUTRIENTS

The Mechanism, In Plain English

The micronutrient conversation is where the evidence hierarchy becomes most important to apply carefully. This is also where the gap between legitimate clinical supplementation and commercial supplement sprawl is widest.

I want to start with a frame that I use with every patient: supplementation for a documented deficiency has a fundamentally different evidence base than supplementation for optimization. When a man with a serum 25-OH vitamin D of 16 ng/mL takes vitamin D, he is correcting a deficiency that is associated with real clinical consequences. When a man with a serum 25-OH vitamin D of 55 ng/mL takes vitamin D, he is adding a nutrient where he already has adequate stores, and the marginal benefit is much less clearly supported. This distinction does not appear in most consumer supplement content because it requires a blood test to apply it correctly.

Vitamin D, magnesium, and omega-3 fatty acids are the three micronutrients with the strongest evidence base in men over 40, each addressing documented deficiencies that affect measurable health outcomes: vitamin D (target serum 25-OH-D: 40–60 ng/mL; deficient in over 40% of American men); magnesium (affects sleep architecture, insulin sensitivity, and cardiac rhythm; deficient in 50–60% of Western men at dietary intake levels; glycinate or malate forms for bioavailability); and omega-3 fatty acids (EPA+DHA at 1g/day or above for cardiovascular and anti-inflammatory effects; the 2024 extension of the VITAL trial confirmed benefit at this dose range).

Vitamin D. The IOM minimum recommendation of 20 ng/mL was set to prevent bone disease. It was not set to optimize cardiovascular, immune, or metabolic function. The evidence base for cardiovascular benefit, which is specifically where I focus, points toward a target range of 40 to 60 ng/mL. Multiple observational studies show associations between 25-OH vitamin D below 30 ng/mL and elevated cardiovascular risk. The VITAL trial found that vitamin D3 supplementation at 2,000 IU/day in adults without prior deficiency testing did not significantly reduce cardiovascular events in the general population, but secondary analyses suggested benefit in men with BMI below 25 and in Black adults with lower baseline levels. The clinical translation: get your level measured, supplement to reach 40 to 60 ng/mL, and the dose required varies enormously between men (some need 1,000 IU to reach target, others need 4,000 or more).

At 4,000 IU per day, vitamin D3 is safe for most adults, as confirmed by the IOM’s tolerable upper intake level of 4,000 IU. Toxicity occurs at sustained doses above 10,000 IU per day combined with high dietary calcium intake. For men asking whether 4,000 IU daily is safe: yes, in the absence of hypercalcemia or granulomatous disease, with periodic monitoring of serum levels.

Magnesium. This is the most underappreciated micronutrient in men’s cardiovascular medicine. Dietary magnesium intake in Western populations is approximately 50 to 60% below the estimated average requirement. Magnesium participates in over 300 enzymatic reactions including ATP synthesis, protein synthesis, DNA repair, blood pressure regulation, and cardiac rhythm regulation. Hypomagnesemia (serum magnesium below 0.7 mmol/L) is associated with atrial fibrillation, ventricular arrhythmia, hypertension, and insulin resistance.

The form of supplemental magnesium matters more than most consumer content acknowledges. Magnesium oxide, the most common over-the-counter form, has approximately 4% absorption. Magnesium glycinate (chelated to glycine) and magnesium malate have absorption rates in the 30 to 50% range and are the clinically preferred forms. Magnesium threonate is marketed for cognitive benefit based on its ability to cross the blood-brain barrier; the cognitive data is early-stage. For sleep, blood pressure, and arrhythmia reduction, magnesium glycinate or malate at 200 to 400 mg elemental magnesium before sleep is the practical recommendation.

Omega-3 fatty acids. The evidence here divides cleanly into two dose ranges and their respective clinical indications.

At standard doses of 1 to 2 grams EPA+DHA per day: anti-inflammatory effect (reduced hs-CRP), modest triglyceride reduction, and probable cardiovascular mortality benefit in deficient populations. The VITAL trial confirmed a relative risk reduction for major cardiovascular events of approximately 17% in men who did not consume much fish at baseline.

At high doses (4 grams EPA as icosapentaenoic acid, i.e., Vascepa/AMR101): the REDUCE-IT trial in 2019 showed a 25% relative risk reduction for major cardiovascular events in men with elevated triglycerides (above 150 mg/dL) and established cardiovascular disease or diabetes, on statin therapy (Bhatt et al., NEJM, 2019). This is a large effect in a high-risk population. The question of whether mineral oil in the placebo arm inflated the treatment effect continues to be debated; the clinical guideline bodies (ACC/AHA) currently endorse this therapy for the specific high-risk group the trial targeted.

For most men without established cardiovascular disease: 1 to 2 grams EPA+DHA per day from a quality fish oil, taken with a meal containing fat, is a reasonable cardiovascular and anti-inflammatory supplementation choice with a Promising (2) evidence rating.

Beyond the Big Three. Several other micronutrients deserve brief evaluation in this population.

Zinc: For men with documented deficiency (common in men who sweat heavily, follow plant-forward diets, or take proton pump inhibitors), zinc repletion supports testosterone synthesis (zinc is a cofactor for LH signaling and steroid synthesis), immune function, and wound healing. For men with adequate zinc levels, supplementation produces no additional benefit in testosterone or immune function. Dose: 15 to 25 mg elemental zinc per day. Higher doses compete with copper absorption and should be paired with 1 to 2 mg copper supplementation.

Vitamin K2 (MK-7): K2 activates matrix Gla protein (MGP), which inhibits vascular calcification. The evidence for K2 reducing cardiovascular calcification progression is Promising (2), sufficient to justify supplementation as a candidate intervention in men with existing coronary calcium or high calcification risk, not sufficient to recommend universally. Dose studied: 180 to 360 mcg MK-7 per day.

CoQ10: Relevant for men on statin therapy, where statin-associated myalgia is a real clinical problem affecting 5 to 10% of users. CoQ10 depletion is the proposed mechanism; the evidence for CoQ10 supplementation preventing or treating statin myalgia is inconsistent but sufficient that a 3-month trial at 100 to 200 mg per day is reasonable before attributing myalgia to the statin itself. For cardiovascular outcomes in non-statin users: Early (3) evidence.

NMN (Nicotinamide Mononucleotide) and NAD+ precursors broadly: This is where the evidence diverges most sharply from the marketing language. David Sinclair’s work on NAD+ and longevity is intellectually compelling and has been influential in moving the research field forward. The commercial extrapolation to NMN supplementation as a longevity intervention in healthy humans is not supported by the current human evidence base. Sinclair’s own research has been the subject of concerns about data integrity in multiple papers, and his public promotion of NMN as a personal supplement while publishing research on NAD+ precursors creates a conflict that consumers should note ([Sinclair Lab, various publications, 2022–2024]). NMN at commercially available doses has demonstrated modest elevations in circulating NAD+ levels; it has not demonstrated lifespan extension, cognitive benefit, or cardiovascular outcome improvement in adequately powered human trials. Rating: Theoretical (4).

Micronutrient Honesty Scale

• Vitamin D3 supplementation to achieve serum 25-OH-D of 40–60 ng/mL: Promising (2), Evidence for cardiovascular benefit requires reaching the target range; effect in men with adequate baseline levels is less clear.

• Magnesium glycinate/malate (200–400mg elemental) for sleep quality and blood pressure: Promising (2), Multiple small-to-moderate RCTs; consistent directional effect on sleep onset, blood pressure, and insulin sensitivity in deficient men.

• Omega-3 (EPA+DHA 1–2g/day) for general cardiovascular and anti-inflammatory benefit: Promising (2), VITAL trial confirmed benefit in fish-low-consuming men; not universal in adequately nourished populations.

• Omega-3 (icosapentaenoic acid 4g/day) for high-risk men with elevated triglycerides on statin therapy: Solid (1), REDUCE-IT trial; 25% relative risk reduction for major cardiovascular events. This is prescription therapy, not OTC supplementation (Bhatt et al., NEJM, 2019).

• Vitamin K2 MK-7 for vascular calcification attenuation: Promising (2), Mechanistically supported; RCT evidence for slowing coronary calcification is early but directionally consistent.

• CoQ10 for statin-associated myalgia: Early (3), Inconsistent but plausible; reasonable 3-month trial before attributing myalgia to statin.

• NMN for longevity, cognitive function, or cardiovascular outcomes: Theoretical (4), Human trial evidence is insufficient for any meaningful clinical endpoint. Promoted primarily on preclinical data and conflict-of-interest-compromised research.

• Gary Brecka’s five-gene methylation panel ($599) for supplement personalization: Unsupported (5), The claimed precision of nutrient protocol derivation from MTHFR and four other common variants is not supported by evidence. MTHFR heterozygosity is present in 40–60% of the population with no proven need for supplement intervention beyond adequate folate intake. The commercial interpretation of these variants exceeds the science.

What the Other Voices Get Wrong

Peter Attia’s supplement protocols are among the most mechanistically rigorous in the consumer health space. His explanations of rapamycin, mTOR, senolytic compounds, and NAD+ biology are drawn from credible primary sources. The failure mode is complexity: a man who follows Attia’s supplement content will conclude that optimizing supplementation requires quarterly bloodwork, a concierge physician, $600 per month in supplements, and a working understanding of molecular biology. This framing, while intellectually honest, effectively excludes the men who most need the supplementation information: middle-income, time-poor, physician-access-limited men over 40 who need a prioritized, evidence-ranked list they can act on this week (Attia, nytimes.com/2026/02/07/opinion/peter-attia-epstein-health-influencer.html).

Andrew Huberman and Andy Galpin’s supplement content, including their “Foundational Supplements” protocol, includes several well-supported interventions (vitamin D, magnesium, omega-3) and several early-evidence interventions (tongkat ali, ashwagandha, fadogia agrestis for testosterone support) mixed together without clear evidence grading. The absence of an evidence hierarchy means that a man following this protocol treats a Solid (1) intervention (magnesium) with the same weight as a Theoretical (4) intervention (fadogia agrestis), because they appear in the same list endorsed by the same voice. After the 2024 allegations against Huberman substantially damaged his credibility with a segment of his audience, the men who built their health protocols around his recommendations have found themselves in a trust vacuum with no framework for evaluating what to keep (Nymag.com/intelligencer, Huberman allegations).

David Sinclair’s promotion of NMN deserves direct acknowledgment: he has been publicly taking NMN and promoting it as a personal longevity intervention for nearly a decade, while publishing research on NAD+ precursors in his own laboratory. The evidence for NMN as a human longevity intervention remains Theoretical (4). The conflict between his commercial positioning, which has materially benefited NMN supplement companies, and the actual clinical evidence base is a specific example of the credentialed-expert-as-commercial-amplifier problem that SDE’s Honesty Scale is designed to address.

Bryan Johnson’s supplementation stack, 111 compounds in the Blueprint protocol, is the reductio ad absurdum of the optimization framework. The individual components often have reasonable scientific rationales. The aggregate, taken at face value, implies that human health optimization requires constant self-experimentation, continuous biomarker tracking, and financial resources available to perhaps 0.001% of men. The collateral damage is real: men who follow Bryan Johnson’s content and cannot replicate his protocol feel that they are failing at health by virtue of inadequate resources, when in fact the three-supplement priority (vitamin D to target, magnesium glycinate at night, omega-3 1–2g with food) is accessible to almost everyone and is supported by the strongest available human evidence (Don’t Die, dontdie.com).

Paul Saladino’s Heart & Soil organ supplements are marketed on the premise that organ meats are the most nutrient-dense foods available, which is true in some respects, and that desiccated organ capsules replicate this density, which is commercially convenient but not specifically supported relative to dietary organ meat consumption or well-studied individual micronutrient supplementation.

Cardiologist’s Note

There are two supplements that I want to address directly from a cardiovascular medicine standpoint that are underemphasized in the broader conversation.

Magnesium is, in my clinical view, the most underutilized supplement in men’s cardiac care. I have seen patients with recurrent atrial fibrillation, after ablation and antiarrhythmic drug trials, whose episode frequency declined substantially after magnesium optimization to the high-normal range (0.9 to 1.0 mmol/L serum, though intracellular magnesium better reflects tissue stores). I am not claiming magnesium cures atrial fibrillation. I am saying that magnesium deficiency is extraordinarily common, the supplement is inexpensive and safe, and its role in cardiac conduction, blood pressure regulation, and insulin sensitivity is severely underappreciated in consumer health content.

Omega-3 fatty acids at prescription dose (4g EPA) are an intervention that many cardiologists underutilize because the REDUCE-IT trial’s mineral oil placebo controversy has introduced uncertainty. My clinical reading: the magnitude of effect, 25% relative risk reduction in a well-defined high-risk population, is too large to attribute entirely to placebo arm inflation. For a man over 40 with triglycerides above 150 on statin therapy who has established cardiovascular disease or diabetes, this is a conversation worth having with your cardiologist (Bhatt et al., NEJM, 2019).

What to Do This Week

This is not a 27-item supplement checklist. It is a three-step protocol for men who want to use the evidence, not the marketing.

Step 1: Get the three blood tests that tell you what you actually need. Request serum 25-OH vitamin D (target: 40–60 ng/mL), serum magnesium (target: high-normal range 0.85–1.0 mmol/L), and a fasting lipid panel with triglycerides. These three values tell you whether vitamin D and magnesium supplementation is correction of deficiency or addition to adequacy, and whether you are in the triglyceride range where high-dose omega-3 is indicated.

Step 2: Build the three-supplement foundation based on your lab results. Vitamin D3: dose adjusted to reach 40–60 ng/mL (most men need 2,000–4,000 IU/day; check your level in 90 days). Magnesium glycinate or malate: 200–400 mg elemental magnesium before sleep. Omega-3 EPA+DHA: 1–2 grams per day with a fat-containing meal. These three supplements, based on documented population-level deficiencies with cardiovascular relevance, are the foundation before anything else is added.

Step 3: Audit your existing stack before your next purchase. Take your current supplement list and apply the SDE Honesty Scale: is there a primary citation? What was the study population, dose, and outcome? Is the evidence rating Solid (1) or Promising (2)? Anything rated Early (3) or below should require a specific reason for you to continue it. Cancel any subscription you cannot justify at this level. Then do not replace it with something from a podcast recommendation without applying the same question.

Step 4: If you take creatine, keep taking creatine. Three to five grams of creatine monohydrate per day is the best-evidenced, safest, and most practically useful supplement in the stack for a man over 40 who does any resistance training. The hair loss concern is not supported by replicated evidence at standard doses. The kidney concern is not supported by evidence in healthy men. Keep taking it.

Step 5: For protein, treat it as food strategy, not supplement strategy. The goal is 1.6–2.2 g/kg/day, distributed across meals with at least 25–40g protein each. If you cannot reach this through food, protein powder is a convenient and inexpensive tool. Use it to hit the target, not to exceed it.

Step 6: Put NMN, longevity peptides, and senolytic compounds in the “interesting but not yet clinical” category. Check back in three years. The research is genuinely interesting. The human evidence at commercial doses is not yet at the level that justifies prioritizing these above the three-supplement foundation. If you are currently spending $80/month on NMN, redirect that money to a coronary calcium score.

Step 7: Do not let the perfect protocol be the enemy of the adequate one. The three-supplement foundation (vitamin D to target, magnesium glycinate at night, omega-3 with food) plus creatine if you train and adequate dietary protein is a protocol that any cardiologist, sports medicine physician, or evidence-based family practitioner would endorse. It requires no concierge physician. It costs approximately $35 to $50 per month. It is the floor, and for most men it is also sufficient.

The Featured Snippet Block

Does creatine cause hair loss in men?

No replicated evidence supports this claim at standard doses. The one study associating creatine with elevated DHT (a hormone linked to hair loss) used a loading dose of 25 g/day, three to five times the standard therapeutic dose, and measured a hormonal surrogate, not actual hair loss. No participant in that study lost hair. No subsequent study has replicated the DHT elevation at 3–5 g/day. Creatine monohydrate at standard doses is among the safest supplements in existence.

How much protein should a 45-year-old man eat per day?

Men over 40 should target 1.6–2.2 grams of protein per kilogram of body weight per day to counteract anabolic resistance, the age-related decline in muscle protein synthesis efficiency. For an 85 kg (187 lb) man, this is approximately 136–187 grams per day, roughly double the RDA. This protein should be distributed across 3–4 meals of at least 25–40g each to reach the leucine threshold required to activate muscle protein synthesis.

What is the best creatine dose for men over 40?

Creatine monohydrate at 3–5 grams per day, taken consistently, is the evidence-supported dose. No loading phase is required for long-term use; loading accelerates initial muscle creatine saturation but is not necessary and may increase gastrointestinal discomfort. Timing is flexible; consistent daily intake matters more than peri-workout timing.

When to Call Your Cardiologist

Supplements become a cardiology conversation under specific conditions.

You are taking high-dose niacin (1,500 mg or above) for lipid management. Niacin at these doses raises HDL and lowers triglycerides but also carries a significant hepatotoxicity risk and, per the AIM-HIGH and HPS2-THRIVE trials, does not reduce cardiovascular events beyond statin therapy. Your cardiologist should know if you are taking this.

You are taking high-dose omega-3 (4g/day as prescription icosapentaenoic acid) without cardiologist supervision. This is a prescription-strength cardiovascular intervention with a specific clinical indication (triglycerides above 150, established cardiovascular disease or diabetes, on statin therapy). It should be prescribed and monitored, not self-initiated.

You are taking herbal or plant-based supplements with known interactions with anticoagulants, antiplatelets, or antiarrhythmic drugs. Specifically: St. John’s Wort (significant CYP3A4 inducer, reduces plasma levels of statins, warfarin, and other medications); fish oil at high doses with anticoagulants (increased bleeding risk); ginkgo biloba (antiplatelet effect). If you are on any cardiovascular medication, your cardiologist needs a complete supplement list at every visit.

You are spending significant money on supplements while not having had a coronary calcium score in your 40s, and you have cardiovascular risk factors. The CAC score costs $75 to $200 out of pocket, is not covered by most insurance, and provides the single most useful piece of cardiac risk information available to a man in his 40s. If the supplement budget could partially fund that conversation, it should.

Close

I want to return to the two men from my opening scene.

The developer with twenty-seven supplements and a $220 monthly bill left his appointment with a different list. Six items: vitamin D (dosed to target), magnesium glycinate before bed, omega-3 twice daily with food, creatine if he started lifting, an adequate protein target, and a coronary calcium score scheduled for the following month. He canceled fourteen supplement subscriptions that afternoon.

The project manager who had stopped creatine because of the hair loss study started taking it again the following morning. His sleep, which had not been caused by creatine withdrawal (because there is no such thing), improved when he addressed the sleep hygiene issues we found when we talked further.

Two men. Both had been failed by the same system that sells them complexity instead of clarity.

The SDE Honesty Scale is not a feature. It is a clinical obligation. Every month in the Stop Dying Early newsletter, I apply it to a different supplement claim, protocol, or emerging compound. Not to tell men what to buy. To tell men what the evidence actually says, without the commercial relationship distorting the answer.

The Vascular Clock Membership includes a monthly SDE Honesty Scale review. It is built for men who want to stay current on the supplement evidence without having to watch a two-hour podcast to extract three actionable data points.

The newsletter is free. The commitment is one email per week. The promise is that nothing I recommend will be something I profit from recommending.

ABERA: in Ekegusii, the willingness to set down what is heavy when it is not serving you.

Twenty-seven supplements is heavy.

Set it down.

[Access the SDE Supplement Honesty Review at stopdyingearly.com/supplement-review] [Join the Vascular Clock Membership at stopdyingearly.com/membership] [Join the Stop Dying Early newsletter at stopdyingearly.com/newsletter]